New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
09:03 EDTKINKindred Biosciences announces initiation of pivotal clinical study for SentiKin
Kindred Biosciences announced that it has initiated the pivotal clinical trial for SentiKinfor post-operative pain in dogs. SentiKin is a centrally acting non-opioid, non-steroidal anti-inflammatory and non-steroidal analgesic drug. The proposed mechanism of action of SentiKin's active ingredient is selective potassium channel opening activity with NMDA receptor antagonist properties, with resultant anti-nociceptive, anti-seizure, muscle relaxant, and neuroprotective activities.
News For KIN From The Last 14 Days
Check below for free stories on KIN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
09:07 EDTKINOn The Fly: Pre-market Movers
Subscribe for More Information
08:20 EDTKINKindred Biosciences price target lowered to $19 from $30 at BMO Capital
BMO Capital cut its price target on Kindred after the company announced that its pivotal study of CereKin for the treatment of osteoarthritis in dogs did not meet its primary endpoint. However, the firm thinks that each of two other trials that the company is undertaking has a 70% chance of succeeding. The firm believes that the company has many more shots on goal, and it keeps an Outperform rating on the shares.
August 20, 2014
18:35 EDTKINOn The Fly: After Hours Movers
Subscribe for More Information
16:03 EDTKINKindred reports pivotal field study of CereKin did not meet primary endpoint
Subscribe for More Information
16:00 EDTKINKindred Biosciences trading halted, pending news
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use